Oppenheimer & Co’s Quest Diagnostics DGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $7.59M | Buy |
38,731
+897
| +2% | +$174K | 0.09% | 243 |
|
|
2025
Q4 | $6.57M | Buy |
37,834
+65
| +0.2% | +$11.8K | 0.09% | 245 |
|
|
2025
Q3 | $7.2M | Buy |
37,769
+6
| +0% | +$1.06K | 0.09% | 239 |
|
|
2025
Q2 | $6.78M | Buy |
37,763
+72
| +0.2% | +$12.5K | 0.09% | 243 |
|
|
2025
Q1 | $6.38M | Sell |
37,691
-6,832
| -15% | -$1.12M | 0.1% | 225 |
|
|
2024
Q4 | $6.72M | Sell |
44,523
-866
| -2% | -$135K | 0.1% | 211 |
|
|
2024
Q3 | $7.05M | Sell |
45,389
-2,933
| -6% | -$438K | 0.11% | 207 |
|
|
2024
Q2 | $6.61M | Sell |
48,322
-199
| -0.4% | -$27.3K | 0.11% | 214 |
|
|
2024
Q1 | $6.46M | Sell |
48,521
-1,353
| -3% | -$176K | 0.11% | 227 |
|
|
2023
Q4 | $6.88M | Buy |
49,874
+33
| +0.1% | +$4.34K | 0.13% | 188 |
|
|
2023
Q3 | $6.07M | Sell |
49,841
-456
| -0.9% | -$60.8K | 0.13% | 196 |
|
|
2023
Q2 | $7.07M | Sell |
50,297
-1,568
| -3% | -$216K | 0.14% | 165 |
|
|
2023
Q1 | $7.34M | Sell |
51,865
-5,263
| -9% | -$753K | 0.16% | 151 |
|
|
2022
Q4 | $8.94M | Sell |
57,128
-3,956
| -6% | -$568K | 0.2% | 109 |
|
|
2022
Q3 | $7.49M | Sell |
61,084
-1,659
| -3% | -$218K | 0.18% | 131 |
|
|
2022
Q2 | $8.34M | Buy |
62,743
+2,166
| +4% | +$295K | 0.18% | 121 |
|
|
2022
Q1 | $8.29M | Buy |
60,577
+3,792
| +7% | +$529K | 0.15% | 145 |
|
|
2021
Q4 | $9.82M | Sell |
56,785
-59
| -0.1% | -$8.98K | 0.17% | 121 |
|
|
2021
Q3 | $8.26M | Buy |
56,844
+1,017
| +2% | +$149K | 0.15% | 142 |
|
|
2021
Q2 | $7.37M | Sell |
55,827
-376
| -0.7% | -$49.2K | 0.13% | 170 |
|
|
2021
Q1 | $7.21M | Buy |
56,203
+55
| +0.1% | +$6.78K | 0.14% | 155 |
|
|
2020
Q4 | $6.69M | Sell |
56,148
-227
| -0.4% | -$27.7K | 0.14% | 158 |
|
|
2020
Q3 | $6.46M | Sell |
56,375
-153
| -0.3% | -$18.1K | 0.16% | 136 |
|
|
2020
Q2 | $6.44M | Sell |
56,528
-207
| -0.4% | -$22K | 0.17% | 123 |
|
|
2020
Q1 | $4.55M | Buy |
56,735
+504
| +0.9% | +$52.2K | 0.14% | 157 |
|
|
2019
Q4 | $6M | Buy |
56,231
+1,182
| +2% | +$123K | 0.15% | 158 |
|
|
2019
Q3 | $5.89M | Buy |
55,049
+478
| +0.9% | +$49.1K | 0.16% | 138 |
|
|
2019
Q2 | $5.56M | Sell |
54,571
-660
| -1% | -$63.4K | 0.15% | 153 |
|
|
2019
Q1 | $4.97M | Buy |
55,231
+945
| +2% | +$81.9K | 0.13% | 167 |
|
|
2018
Q4 | $4.52M | Buy |
54,286
+1,638
| +3% | +$154K | 0.14% | 158 |
|
|
2018
Q3 | $5.68M | Sell |
52,648
-443
| -0.8% | -$48.6K | 0.14% | 162 |
|
|
2018
Q2 | $5.84M | Sell |
53,091
-6,397
| -11% | -$666K | 0.16% | 142 |
|
|
2018
Q1 | $5.97M | Sell |
59,488
-92
| -0.2% | -$9.42K | 0.15% | 149 |
|
|
2017
Q4 | $5.87M | Buy |
59,580
+708
| +1% | +$67.1K | 0.15% | 156 |
|
|
2017
Q3 | $5.51M | Sell |
58,872
-215
| -0.4% | -$22.8K | 0.15% | 161 |
|
|
2017
Q2 | $6.57M | Buy |
59,087
+818
| +1% | +$86.5K | 0.18% | 128 |
|
|
2017
Q1 | $5.72M | Sell |
58,269
-1,174
| -2% | -$112K | 0.16% | 144 |
|
|
2016
Q4 | $5.46M | Buy |
59,443
+667
| +1% | +$57.5K | 0.16% | 152 |
|
|
2016
Q3 | $4.97M | Buy |
58,776
+1,835
| +3% | +$154K | 0.15% | 163 |
|
|
2016
Q2 | $4.63M | Sell |
56,941
-4,377
| -7% | -$333K | 0.14% | 165 |
|
|
2016
Q1 | $4.38M | Buy |
61,318
+6,087
| +11% | +$408K | 0.13% | 176 |
|
|
2015
Q4 | $3.93M | Buy |
55,231
+2,501
| +5% | +$168K | 0.12% | 197 |
|
|
2015
Q3 | $3.24M | Buy |
52,730
+1,510
| +3% | +$106K | 0.1% | 235 |
|
|
2015
Q2 | $3.71M | Buy |
51,220
+41,591
| +432% | +$3.07M | 0.1% | 235 |
|
|
2015
Q1 | $740K | Sell |
9,629
-594
| -6% | -$42.5K | 0.02% | 719 |
|
|
2014
Q4 | $686K | Buy |
10,223
+6,372
| +165% | +$402K | 0.02% | 718 |
|
|
2014
Q3 | $234K | Sell |
3,851
-3,750
| -49% | -$231K | 0.01% | 1181 |
|
|
2014
Q2 | $446K | Buy |
7,601
+3,400
| +81% | +$199K | 0.01% | 891 |
|
|
2014
Q1 | $243K | Buy |
+4,201
| New | +$225K | 0.01% | 1140 |
|
|
2013
Q3 | – | Sell |
-4,602
| Closed | -$279K | – | 1321 |
|
|
2013
Q2 | $279K | Buy |
+4,602
| New | +$274K | 0.01% | 959 |
|
Other funds holding DGX
VCM
VPM
EIG
Oppenheimer & Co's DGX Position: Q1 2026 in Review
Oppenheimer & Co increased its Quest Diagnostics (DGX) stake by 2.4% in Q1 2026, buying an estimated $174K and bringing the position to 38,731 shares worth $7.59M. The position accounts for 0.09% of the portfolio, ranked #243.
Oppenheimer & Co first reported a position in DGX in Q2 2013 and has held it in 50 quarters since. The position peaked at $9.82M in Q4 2021. 1,065 funds tracked by Wall St. Rank hold DGX as of Q1 2026.
- Oppenheimer & Co held 38,731 shares of Quest Diagnostics worth $7.59M as of Q1 2026.
- Oppenheimer & Co bought 897 Quest Diagnostics shares in Q1 2026, an estimated $174K.
- Quest Diagnostics made up 0.09% of Oppenheimer & Co's portfolio in Q1 2026, its #243 holding.
- Oppenheimer & Co first reported a position in Quest Diagnostics in Q2 2013 and has held it in 50 quarters since.
- Oppenheimer & Co's Quest Diagnostics position peaked at $9.82M in Q4 2021.
- 1,065 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.
Based on Oppenheimer & Co's 13F filing for Q1 2026, filed 24 Apr 2026.